{"title":"Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.","authors":"A Tomida, T Tsuruo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Most solid tumors show resistance to current chemotherapy. This drug resistance can be associated with the unique physiology of solid tumors. Solid tumors generally have regions of low oxygen (hypoxia), low pH and low levels of glucose, which are not observed in normal tissues. These tumor-specific conditions commonly cause the glucose-regulated stress response of cancer cells. Accumulating evidence shows that the stress response leads to induction of resistance to multiple drugs, such as etoposide, doxorubicin, camptothecin and vincristine. This type of drug resistance is reversible and decays rapidly when stress conditions are removed. The induction of drug resistance can be partly explained by cell cycle arrest at the G1 phase in stressed cells because most anticancer drugs are primarily effective against rapidly dividing cells. Specific mechanisms, such as the decreased expression of DNA topoisomerase (topo) II alpha for the resistance to topo II poisons, are also involved in the drug resistance. Stressed cells, however, become hypersensitive to cisplatin, one of the most effective drugs against solid tumors, suggesting that preferential cytotoxicity to stressed cells may be important for the clinical efficacy against solid tumors. Further characterization of stressed cells will provide a unique target to circumvent the drug resistance of solid tumors.</p>","PeriodicalId":7927,"journal":{"name":"Anti-cancer drug design","volume":"14 2","pages":"169-77"},"PeriodicalIF":0.0000,"publicationDate":"1999-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer drug design","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Most solid tumors show resistance to current chemotherapy. This drug resistance can be associated with the unique physiology of solid tumors. Solid tumors generally have regions of low oxygen (hypoxia), low pH and low levels of glucose, which are not observed in normal tissues. These tumor-specific conditions commonly cause the glucose-regulated stress response of cancer cells. Accumulating evidence shows that the stress response leads to induction of resistance to multiple drugs, such as etoposide, doxorubicin, camptothecin and vincristine. This type of drug resistance is reversible and decays rapidly when stress conditions are removed. The induction of drug resistance can be partly explained by cell cycle arrest at the G1 phase in stressed cells because most anticancer drugs are primarily effective against rapidly dividing cells. Specific mechanisms, such as the decreased expression of DNA topoisomerase (topo) II alpha for the resistance to topo II poisons, are also involved in the drug resistance. Stressed cells, however, become hypersensitive to cisplatin, one of the most effective drugs against solid tumors, suggesting that preferential cytotoxicity to stressed cells may be important for the clinical efficacy against solid tumors. Further characterization of stressed cells will provide a unique target to circumvent the drug resistance of solid tumors.
大多数实体瘤对目前的化疗有耐药性。这种耐药性可能与实体瘤独特的生理特性有关。实体瘤通常有低氧(缺氧)、低pH值和低水平葡萄糖的区域,这些在正常组织中没有观察到。这些肿瘤特异性条件通常会引起癌细胞的葡萄糖调节应激反应。越来越多的证据表明,应激反应导致对多种药物的耐药,如依托泊苷、阿霉素、喜树碱和长春新碱。这种类型的耐药性是可逆的,并且在压力条件消除后迅速衰减。由于大多数抗癌药物主要对快速分裂的细胞有效,因此在应激细胞的G1期细胞周期阻滞可以部分解释耐药性的诱导。特定的机制,如DNA拓扑异构酶(topo) II α的表达降低对topo II毒物的抗性,也涉及耐药。然而,应激细胞对顺铂(最有效的实体瘤药物之一)产生超敏反应,提示对应激细胞的优先细胞毒性可能对实体瘤临床疗效有重要影响。进一步表征应激细胞将提供一个独特的靶点,以规避实体瘤的耐药性。